



---

*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

## Revision of Precautions Atovaquone

January 12, 2016

### **Non-proprietary name**

Atovaquone

### **Safety measure**

Precautions should be revised in the package insert.

In the Clinically significant adverse reaction subsection of the Adverse reaction section, the following text should be added (underlined parts are revised):

#### Agranulocytosis and leukopenia:

Agranulocytosis or leukopenia may occur. Patients should be carefully monitored. If any abnormalities are observed, administration of this drug should be discontinued and appropriate measures should be adopted.